Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep - New Biomarker Data from TACTI-002 trial in 1st line NSCLC (ASX:IMM)

Statistically significant increases of Th1 biomarkers (IFN-gamma, CXCL-10), circulating immune cells (lymphocytes), and RNA levels of immune activating genes were observed...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

Excellent survival benefit in 1st line non-small cell lung cancer (1L NSCLC) in TACTI-002 trial: median Overall Survival of 35.5 months (TPS ≥1% patients) providing additional 12-18 mon...read more

Immutep receives Australian R&D Tax Incentive (ASX:IMM)

SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,134,882 cash rebate from the Aust...read more

Immutep - Results of Meeting (ASX:IMM)

SYDNEY, AUSTRALIA – 24 October 2023 – Immutep Limited (ASX:IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) advises that the results of its Annual General Meeting (...read more

Immutep reports promising data from INSIGHT-003 trial (ASX:IMM)

Promising efficacy and tolerability reported from efti plus anti-PD-1 therapy and doublet chemotherapy as first line therapy in metastatic non-squamous non-small cell lung cancer con...read more

Immutep AGM 2023 - Chairman's Address (ASX:IMM)

Dear Fellow Shareholders, It’s my pleasure to welcome all our shareholders to Immutep’s Annual General Meeting 2023, a year that has seen Immutep report very encouraging clinical data...read more

Immutep AGM 2023 - CEO's Presentation (ASX:IMM)

To view the presentation, download the attached PDF.

Immutep - Webcast slides for new Efti clinical data in 1st line NSCLC (ASX:IMM)

To view the presentation, download the attached PDF.

Immutep - Excellent Overall Survival in Non-Small Cell Lung Cancer (ASX:IMM)

Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1%), 23.4 months in patients with...read more

Immutep announces publication of ESMO 2023 abstracts (ASX:IMM)

New updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Saturday, October 21st, at 9:05 CEST Immute...read more

Immutep announces acceptance of abstract for SITC 2023 (ASX:IMM)

SYDNEY, AUSTRALIA – 3 October 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing...read more

Immutep - Commercial Scale Manufacturing of Efti for Clinical Trials (ASX:IMM)

SYDNEY, AUSTRALIA – September 21, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company develop...read more

Immutep - 2023 AGM & Key Dates (ASX:IMM)

SYDNEY, AUSTRALIA – 8 September 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) advises that in accordance with ASX Listing Rule 3.13.1, that it intends to hold its 2023 Annual General M...read more

Immutep to Participate in September Investor Conferences (ASX:IMM)

SYDNEY, AUSTRALIA – 6 September 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical stage biotechnology company developing nov...read more